Mobocertinib is a targeted therapy for non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, developed by Takeda Pharmaceutical of Japan. This article will introduce in detail the use, purchase channels and storage conditions of Mobocertinib from three aspects: drug guidelines, drug purchase guidelines and storage guidelines, so as to help patients and their families better understand this drug.
Guidelines for the use of Mobocertinib
Rational use of Mobocertinib is key to determining the efficacy of treatment. The following content will introduce its dosage, adverse reactions and precautions in detail to help patients take the medication correctly.
Dosage
The recommended dose of Mobocertinib is 160 mg orally once daily until disease progression or unacceptable toxicity. The medicine should be swallowed whole and avoid opening or chewing the capsule. If you miss a dose for more than 6 hours, you do not need to make up the dose, and you can take the next dose as originally planned. If vomiting occurs during the medication, there is no need for additional doses, and the medicine can be taken normally the next day.
Adverse reactions and management
Common adverse reactions of Mobocertinib include diarrhea, rash, nausea, fatigue, etc., and laboratory tests may reveal lymphopenia or electrolyte abnormalities. If diarrhea develops, prompt use of antidiarrheal drugs and electrolyte replacement is recommended. For serious adverse reactions, such as prolonged QTc or interstitial lung disease, immediate medical attention should be sought and medication regimen adjusted according to the doctor's advice.
Rational medication is the basis for successful treatment, and patients need to strictly follow the doctor's instructions, monitor their physical condition regularly, and deal with adverse reactions in a timely manner.
Guidelines for the purchase of Mobocertinib
Mobocertinib is available in China, but it is not yet covered by medical insurance. Patients can purchase through a variety of channels, but they need to pay attention to the authenticity and quality of the drug.
Where to buy?
The original drug of Mobocertinib is produced by Takeda Corporation of Japan and is divided into two specifications: the original version in Japan and the clinical version in Hong Kong. Generic drugs are produced by Lucius Laos and Bokron in Paraguay. Patients can purchase through tertiary hospitals, regular pharmacies or cross-border e-commerce platforms, but they need to choose reputable institutions to avoid buying counterfeit or inferior drugs.
Price comparison
The price of the original drug is higher, with the original Japanese version of 40mg*120 tablets and the Hong Kong clinical version of 40mg*30 tablets. The price of generic drugs is relatively low. Patients can choose the appropriate version according to their financial conditions.
When purchasing drugs, it is necessary to carefully screen the source of drugs, clarify the quality of drugs, and choose the appropriate purchase channels and versions according to their own conditions.
Guidelines for the storage of Mobocertinib
Proper storage can confirm the efficacy and safety of Mobocertinib. The following will introduce the storage conditions and precautions in detail.
Storage conditions
Mobocertinib needs to be stored in a light-shielded seal at 20°C-25°C, allowing for short-term transportation at temperatures between 15°C and 30°C. Avoid exposing the drug to extreme temperatures or humidity to prevent the drug from spoiling.
Packing & Inspection
Medicines should be kept in their original containers and should not be mixed with other medicines. Check the integrity of the packaging regularly and contact your doctor or pharmacist if you find any damage or abnormality.
The correct storage method can effectively extend the expiration date of the drug and clarify the therapeutic effect. Patients should store the drug in strict accordance with the requirements to avoid reduced efficacy or ineffectiveness due to improper storage.
